HC Wainwright Brokers Reduce Earnings Estimates for CVKD

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Research analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Cadrenal Therapeutics in a report issued on Friday, August 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.93) per share for the quarter, down from their prior forecast of ($0.65). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($4.01) per share. HC Wainwright also issued estimates for Cadrenal Therapeutics’ Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.92) EPS, FY2027 earnings at ($3.26) EPS and FY2028 earnings at ($1.92) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.28.

Several other analysts also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $13.00.

Cadrenal Therapeutics Stock Performance

Cadrenal Therapeutics stock opened at $1.76 on Tuesday. Cadrenal Therapeutics has a one year low of $1.71 and a one year high of $14.64. The company has a 50-day simple moving average of $2.66 and a 200-day simple moving average of $4.76. The firm has a market capitalization of $6.02 million, a P/E ratio of -0.36 and a beta of 1.84.

Insiders Place Their Bets

In related news, CEO Quang X. Pham sold 12,996 shares of Cadrenal Therapeutics stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $3.94, for a total transaction of $51,204.24. Following the transaction, the chief executive officer directly owned 136,381 shares of the company’s stock, valued at $537,341.14. The trade was a 8.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 87,726 shares of company stock worth $333,575 over the last ninety days. Company insiders own 14.59% of the company’s stock.

Hedge Funds Weigh In On Cadrenal Therapeutics

Large investors have recently made changes to their positions in the business. DRW Securities LLC acquired a new position in shares of Cadrenal Therapeutics in the 4th quarter worth approximately $171,000. Citadel Advisors LLC acquired a new stake in Cadrenal Therapeutics during the third quarter valued at approximately $274,000. Geode Capital Management LLC boosted its holdings in Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after buying an additional 1,818 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in Cadrenal Therapeutics in the third quarter worth approximately $103,000. Institutional investors own 7.92% of the company’s stock.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.